Message boards index | Help | Search messages | Sign in


+ UKCAB + Public area + News, events, announcments + EMA Consultation: Reflection paper on the pharmaceutical development of medicine

EMA Consultation: Reflection paper on the pharmaceutical development of medicine

Print
Pages: 1

Paul Clift
Member
Posts: 467
EMA Consultation: Reflection paper on the pharmaceutical development of medicine
Posted on: December 6 2017, 11:02 am


The European Medicines Agency has released for public consultation Reflection paper on the pharmaceutical development of medicines for use in the older population.

According to Eurostat, the older population in the European Union is expected to grow from around 84 million in 2008 to approximately 141 million by 2050. The very elderly constitute the fastest growing subset. Older people differ from children and adults of younger or middle age with respect to an increased prevalence of gradually declining human organ and body functions, resulting in physical, physiological and/or cognitive impairments, multi- and co-morbidities, and/or frailty. As any such impairments may start at a different chronological age, occur in different orders, and worsen in different rates, older people of the same chronological age can be quite different (e.g. healthy, facing some minor impairments only, frail). In general, older people are the majority users of many medicines and at highest risk of encountering practical medication (usability) problems, which may increase the risk for poor adherence, medication errors and/or reduced patient or caregiver quality of life. Considering the above, it is essential that the needs of older (and especially frail) people are duly considered in the pharmaceutical development of medicines that may be used in the older population.

This reflection paper is intended to communicate the current status of discussions on the pharmaceutical development of medicines that may be used in the older population, and to invite comments on the topics addressed. The paper is not intended to provide regulatory or scientific guidance, although it may contribute to any such development in the future. It is expected that the paper will be read in conjunction with the existing directives, regulations, European Commission, ICH, CHMP and EMA guidelines, Q&A documents and other documents of relevance as linked to or published on the EMA website (www.ema.europa.eu). The examples in this paper should neither be understood as an exhaustive list nor as the only possible options to address a specific topic.

You can access the document here http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500232782&murl=menus/document_library/document_library.jsp&mid=0b01ac058009a3dc.

The deadline for this consultation is the 31 January 2018 and should be provided using this template. The completed comments form should be sent to qwp@ema.europa.eu.

Please note that EMA may collect and further process some personal data of stakeholders and interested parties who submit contributions to the consultations. For more information, see Specific privacy statement for public consultations.

For more information on the European regulatory system for medicines, please consult our brochure.
We would be grateful if you could disseminate this email to anyone else who might be interested in this document.

With kind regards,
Ivan Sebest
Stakeholders and Communication Division

European Medicines Agency
30 Churchill Place
London, E14 5EU
United Kingdom

ivan.sebest@ema.europa.eu
Logged
Ben Cromarty
Member
Posts: 451
Re: EMA Consultation: Reflection paper on the pharmaceutical development of medicine
Reply #1 on: December 7 2017, 10:35 am

Hi, Paul...

...I was going to read this, but the statement below is a bit daunting...:

It is expected that the paper will be read in conjunction with the existing directives, regulations, European Commission, ICH, CHMP and EMA guidelines, Q&A documents and other documents of relevance as linked to or published on the EMA website (www.ema.europa.eu).

Not sure I'll be able to mange all that!

(...but I'll still try to read the paper anyway)
Logged
Paul Clift
Member
Posts: 467
Re: EMA Consultation: Reflection paper on the pharmaceutical development of medicine
Reply #2 on: December 11 2017, 10:22 am

Ben - you're far too thorough! My own response was 'you can expect what you like but if you think I've time enough to read all that lot as well ...' and just read the paper itself!

All the best
Paul
Logged

Print
Pages: 1

+ UKCAB + Public area + News, events, announcments + EMA Consultation: Reflection paper on the pharmaceutical development of medicine